Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2017.00770
Abstract: Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing… read more here.
Keywords: cross reactivity; 2f5 antibody; hiv; anti gp41 ... See more keywords
Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.983313
Abstract: Many participants in HIV-1 vaccine trials, who have not previously been exposed to or vaccinated against HIV-1, display serum immunoglobulin antibodies that bind the gp41 region of HIV-1 envelope prior to vaccination. Previous studies have… read more here.
Keywords: gp41; hiv; anti gp41; trial ... See more keywords
Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1
Sign Up to like & getrecommendations! Published in 2023 at "Vaccines"
DOI: 10.3390/vaccines11040829
Abstract: We are developing cytotoxic immunoconjugates (CICs) targeting the envelope protein (Env) of the Human Immunodeficiency Virus, type 1 (HIV) to purge the persistent reservoirs of viral infection. We have previously studied the ability of multiple… read more here.
Keywords: ability; anti gp41; immunodeficiency virus; human immunodeficiency ... See more keywords